Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

[1]  W. Catalona,et al.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.

[2]  C. Cuny,et al.  Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. , 1996, Urology.

[3]  B. Tombal,et al.  Free to total prostate‐specific antigen (PSA) ratio is superior to total‐PSA in differentiating benign prostate hypertrophy from prostate cancer , 1996, The Prostate. Supplement.

[4]  O. Nilsson,et al.  Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.

[5]  W. Catalona,et al.  Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. , 1998, The Journal of urology.

[6]  Allen C. Goodman,et al.  Economic considerations of prostate cancer. The role of detection specificity and biopsy reduction , 1995 .

[7]  B. Tombal,et al.  Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA. , 1996, Urology.

[8]  W. Catalona,et al.  Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. , 1994, The Journal of urology.

[9]  H. Lilja,et al.  Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. , 1990, European journal of biochemistry.

[10]  W. Catalona,et al.  Longitudinal screening for prostate cancer with prostate-specific antigen. , 1996, JAMA.

[11]  B. G. Blijenberg,et al.  The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. , 1997, The Journal of urology.

[12]  L. Baert,et al.  Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. , 1996, The Journal of urology.

[13]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[14]  B. Efron.  Better Bootstrap Confidence Intervals , 1987 .

[15]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[16]  B. Efron.  The jackknife, the bootstrap, and other resampling plans , 1987 .

[17]  M. J. Hoeksema,et al.  Cancer mortality rates fall: a turning point for the nation. , 1996, Journal of the National Cancer Institute.

[18]  J. Oesterling,et al.  Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. , 1996, Urology.

[19]  P. Schellhammer,et al.  Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. , 1997, Urology.

[20]  D. Ornstein,et al.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.

[21]  S. Loening,et al.  Analytical performance and clinical validity of two free prostate-specific antigen assays compared. , 1996, Clinical chemistry.

[22]  J. Shaffer,et al.  Analytical performance of the Tandem-R free PSA immunoassay measuring free prostate-specific antigen. , 1997, Clinical chemistry.

[23]  E. Metter,et al.  Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. , 1997, Urology.

[24]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[25]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[26]  J. Oesterling,et al.  Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. , 1995, The Journal of urology.

[27]  M. Brawer,et al.  Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. , 1995, Urology.

[28]  A W Partin,et al.  Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. , 1996, Urology.